Author Affiliations: Departments of Dermatology, Complejo Hospitalario, Toledo, Spain (Dr Sánchez-Moya), and Hospital Universitario La Princesa, Madrid, Spain (Dr Daudén).
A 28-year-old healthy woman with a long history of severe psoriasis refractory to conventional systemic treatments was treated with infliximab. No latent tuberculosis (TB) infection was found at the baseline screening. After the fifth infusion and following unprotected contact with a patient with active TB, she developed a primary TB infection in her lymph nodes. A biopsy of the paratracheal adenopathy was performed, and the infection was confirmed by a positive culture for Mycobacterium tuberculosis on a paratracheal adenopathy biopsy specimen. Infliximab treatment was suspended, and treatment with isoniazid, pyrazinamide, and ethambutol was prescribed for 12 months (an allergy to rifampicin was confirmed by a challenge test). The patient continued treatment with topical agents and phototherapy for 2 years, but owing to poor control of the disease (psoriasis area severity index [PASI], 51.8), ustekinumab treatment was initiated (45 mg at weeks 0 and 4). After 1 month and following excellent results, the patient decided to discontinue the therapy.
Sánchez-Moya AI, Daudén E. Peripheral Lymph Node Recurrence of Tuberculosis After Ustekinumab Treatment. Arch Dermatol. 2012;148(11):1332–1333. doi:10.1001/archdermatol.2012.2958
Dermatology in JAMA: Read the Latest
Customize your JAMA Network experience by selecting one or more topics from the list below.